Mon, Nov 24, 2014, 3:26 AM EST - U.S. Markets open in 6 hrs 4 mins


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • gladpick gladpick Nov 17, 2012 5:37 PM Flag

    How GS-7977+RBV performed in difficult-to-treat group

    "Peginterferon-free regimen of sofosbuvir (GS-7977) plus ribavirin (RBV) for 24 weeks produced sustained virologic response rates at 4 weeks posttreatment (SVR4) in majority of difficult-to-treat patients chronically infected with genotype 1 HCV
    SVR4 77% with full-dose RBV"

    Third, As you commented last week , 7977 and Riba failed miserably as GILD quitely slipped in the results in their last news release based on their reported data quoted below:

    So I suspect when the NIH releases their SVR 12 and SVR 24 the results for these harder to treat group will be even worse. I bet GILD wishes the NIH study could have never taken place because if the result for the easy to treat group was so bad, they hate to see what it is going to look like for these harder to treat patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Success(90s%) or failure(60s%) of this 7977+RBV regimen for GT2/3 is important for the short term longevity of Incivek sales (off-label use for GT1 patients is possible). It is almost certain that they are not seeing the 100% SVR rate for GT2/3 when the treatment time length is 12 or less weeks contrary to their earlier results. If they can show that this most advanced regimen is better in efficacy than 6 mo. Peg/Rbv (80% SVR rate), then the 7977 regimen could reach the market before 2015, and Incivek sales will plummet well before its launch. If the recently released results (in the 60s %) are valid, then the drug can be used only for those patients who cannot tolerate Interferon, and Incivek sales could survive for another year or two until their triple combo (+5885) could become approved in 2016.

111.40-1.49(-1.32%)Nov 21 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.